Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Applied Therapeutics (APLT) FCF Margin (2023 - 2025)

Historic FCF Margin for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to 1840.1%.

  • Applied Therapeutics' FCF Margin rose 172828500.0% to 1840.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 8684.7%, marking a year-over-year decrease of 494016200.0%. This contributed to the annual value of 18528.57% for FY2024, which is 179764500.0% down from last year.
  • Applied Therapeutics' FCF Margin amounted to 1840.1% in Q3 2025, which was up 172828500.0% from 19122.95% recorded in Q3 2024.
  • Over the past 5 years, Applied Therapeutics' FCF Margin peaked at 2549.48% during Q4 2023, and registered a low of 19122.95% during Q3 2024.
  • Over the past 3 years, Applied Therapeutics' median FCF Margin value was 5647.8% (recorded in 2024), while the average stood at 7270.94%.
  • Per our database at Business Quant, Applied Therapeutics' FCF Margin crashed by -93899300bps in 2024 and then soared by 172828500bps in 2025.
  • Over the past 3 years, Applied Therapeutics' FCF Margin (Quarter) stood at 2549.48% in 2023, then plummeted by -850bps to 19122.95% in 2024, then soared by 90bps to 1840.1% in 2025.
  • Its FCF Margin was 1840.1% in Q3 2025, compared to 19122.95% in Q3 2024 and 15690.97% in Q2 2024.